Clinical trialNCT00565266CompletedPhase 3Interventional

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

SponsorMilton S. Hershey Medical CenterEnrollment210Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectiveness of the medication tiotropium bromide combined with a low dose of ICS at maintaining asthma control in people with moderately severe asthma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Elliot Israel, MD
Brigham and Women's Hospital
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Emily A. DiMango, MD
Columbia University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Homer A. Boushey, MD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗
Mario Castro, MD
Washington University School of Medicine
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Monica Kraft, MD
Duke University
Principal Investigator
clinicaltrials.gov ↗
Reuben M. Cherniack, MD
National Jewish Health
Study Chair
clinicaltrials.gov ↗
Richard J. Martin, MD
National Jewish Health
Principal Investigator
clinicaltrials.gov ↗
Robert F. Lemanske, MD
University of Wisconsin, Madison
Principal Investigator
clinicaltrials.gov ↗
Stephen I. Wasserman, MD
University of California, San Diego
Principal Investigator
clinicaltrials.gov ↗
Stephen P. Peters, MD, PhD
Wake Forest University Health Sciences
Principal Investigator
clinicaltrials.gov ↗
William J. Calhoun, MD
University of Texas
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
Brigham & Women'S Hospital
Boston, Massachusetts, United States
Washington University, St. Louis
St Louis, Missouri, United States
Columbia University Health Sciences
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
University of Texas Medical Branch
Galveston, Texas, United States
University of Wisconsin, Madison
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Beclomethasone →Salmeterol →Tiotropium →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2008
Primary completion: 31 May 2010
Completion: 31 May 2010
Last update posted: 2 Jul 2018
Registered enrollment: 210
Registry id: NCT00565266

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.